Earlier in December 2008, ProStrakan Group, a wholly owned subsidiary of Kyowa Hakko Kirin, has licensed Canadian rights for Abstral to Paladin.
Paladin Labs president and CEO Jonathan Ross Goodman said though officially launching today, Abstral has been available to patients and their physicians in Canada for almost 2 months under the compassionate early use program.
"This early experience program with Abstral has seen meaningful and heart-warming quality of life improvements in many patients taking our product," Goodman said.